Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Baxter
Medtronic
Johnson and Johnson
McKinsey

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for BBI503


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug BBI503?

BBI503 is an investigational drug.

There have been 9 clinical trials for BBI503. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2017.

The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are Boston Biomedical, Inc, Sumitomo Dainippon Pharma Oncology, Inc, and Sumitomo Dainippon Pharma Co., Ltd.

There are three US patents protecting this investigational drug and fifty-four international patents.

Recent Clinical Trials for BBI503
TitleSponsorPhase
A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal TumorsBoston Biomedical, IncPhase 2
A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal TumorsSumitomo Dainippon Pharma Oncology, IncPhase 2
A Study of BBI503 in Adult Patients With Advanced Urologic MalignanciesBoston Biomedical, IncPhase 2

See all BBI503 clinical trials

Clinical Trial Summary for BBI503

Top disease conditions for BBI503
Top clinical trial sponsors for BBI503

See all BBI503 clinical trials

US Patents for BBI503

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BBI503 ⤷  Try it Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Try it Free
BBI503 ⤷  Try it Free Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) ⤷  Try it Free
BBI503 ⤷  Try it Free Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BBI503

Drugname Country Document Number Estimated Expiration Related US Patent
BBI503 Australia AU2017261372 2036-05-05 ⤷  Try it Free
BBI503 Canada CA3023278 2036-05-05 ⤷  Try it Free
BBI503 China CN107847398 2036-05-05 ⤷  Try it Free
BBI503 European Patent Office EP3452003 2036-05-05 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Baxter
Medtronic
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.